UTHR Q2 2024 Earnings — United Therapeutics Corporation Revenue & Financial Results | Market Cap Arena

UTHRUnited Therapeutics Corporation

$24B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$715M+19.8% YoY

Gross Profit

$637M89.1% margin

Operating Income

$320M44.7% margin

Net Income

$278M38.9% margin

EPS (Diluted)

$5.85

QoQ Revenue Growth

+5.5%

Cash Flow

Operating Cash Flow

$232M

Free Cash Flow

$187M

Stock-Based Comp.

$50M

Balance Sheet

Total Assets

$6.7B

Total Liabilities

$1.0B

Stockholders' Equity

$5.7B

Cash & Equivalents

$1.4B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$715M	$597M	+19.8%
Gross Profit	$637M	$532M	+19.7%
Operating Income	$320M	$313M	+2.1%
Net Income	$278M	$259M	+7.3%

Revenue Segments

Tyvaso

$398M56%

Remodulin

$147M21%

Orenitram

$107M15%

Unituxin

$52M7%

Adcirca

$6M1%

Product and Service, Other

$5M1%

Geographic Segments

UNITED STATES

$675M94%

Non-US

$40M6%